Published in AIDS on November 13, 2010
Improving data quality and supervision of antiretroviral therapy sites in Malawi: an application of Lot Quality Assurance Sampling. BMC Health Serv Res (2012) 1.08
Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol (2013) 1.04
Definition of a core set of quality indicators for the assessment of HIV/AIDS clinical care: a systematic review. BMC Health Serv Res (2013) 0.78
Remote sensing of HIV care programmes using centrally collected laboratory results: can we monitor ART programme effectiveness? S Afr Med J (2012) 0.77
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet (2011) 5.00
Risk factors for recent HIV infection in Uganda. JAMA (2008) 4.84
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bull World Health Organ (2008) 3.85
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med (2010) 3.53
HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS (2008) 3.52
WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest (2009) 3.33
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Assessing the quality of data aggregated by antiretroviral treatment clinics in Malawi. Bull World Health Organ (2008) 2.62
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi. PLoS One (2010) 2.36
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS (2008) 2.34
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the 'Back-to-Care' project in Lilongwe, Malawi. Trop Med Int Health (2010) 2.28
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Trop Med Int Health (2010) 2.19
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. AIDS (2007) 1.93
Scaling up antiretroviral therapy in Malawi-implications for managing other chronic diseases in resource-limited countries. J Acquir Immune Defic Syndr (2009) 1.91
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine (2008) 1.89
Profile: the Karonga Health and Demographic Surveillance System. Int J Epidemiol (2012) 1.85
A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS One (2007) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS (2005) 1.75
HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Infect (2011) 1.75
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol (2005) 1.72
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol (2008) 1.71
Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health (2012) 1.66
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med (2010) 1.65
HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses (2011) 1.63
High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis (2012) 1.62
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
A national survey of the impact of rapid scale-up of antiretroviral therapy on health-care workers in Malawi: effects on human resources and survival. Bull World Health Organ (2007) 1.53
What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public Health (2010) 1.51
Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS (2012) 1.50
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS (2002) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. Addiction (2011) 1.50
Adapting the DOTS framework for tuberculosis control to the management of non-communicable diseases in sub-Saharan Africa. PLoS Med (2008) 1.49
Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis (2010) 1.47
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr (2008) 1.47
Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J (2010) 1.46
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS (2011) 1.44
Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis (2007) 1.44
Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi. PLoS One (2013) 1.43
Individual, household and community factors associated with HIV test refusal in rural Malawi. Trop Med Int Health (2008) 1.41
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis (2008) 1.40
Different delivery models for antiretroviral therapy in sub-Saharan Africa in the context of 'universal access'. Trans R Soc Trop Med Hyg (2008) 1.40
Adult mortality and probable cause of death in rural northern Malawi in the era of HIV treatment. Trop Med Int Health (2012) 1.38
Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS (2004) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
The estimated burden of HIV/AIDS in Uganda, 2005-2010. AIDS (2008) 1.34
Delivering comprehensive home-based care programmes for HIV: a review of lessons learned and challenges ahead in the era of antiretroviral therapy. Health Policy Plan (2010) 1.32
Are they really lost? "true" status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in Urban Malawi. PLoS One (2013) 1.32
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst (2010) 1.31
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis (2010) 1.28
High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda. J Int AIDS Soc (2013) 1.28
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Is Option B+ the best choice? Lancet (2013) 1.24
The vital signs of chronic disease management. Trans R Soc Trop Med Hyg (2009) 1.24
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc (2011) 1.22
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 1.22
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr (2006) 1.22
Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis (2008) 1.18
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Community-based prevention leads to an increase in condom use and a reduction in sexually transmitted infections (STIs) among men who have sex with men (MSM) and female sex workers (FSW): the Frontiers Prevention Project (FPP) evaluation results. BMC Public Health (2010) 1.15
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15
The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol (2007) 1.15
Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS (2003) 1.14
CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS (2010) 1.14
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
Comparison of HIV prevalence estimates from sentinel surveillance and a national population-based survey in Uganda, 2004-2005. J Acquir Immune Defic Syndr (2009) 1.14
Uganda's new national laboratory sample transport system: a successful model for improving access to diagnostic services for Early Infant HIV Diagnosis and other programs. PLoS One (2013) 1.13